Immutep Ltd has released a press release.
TACTI-003 trial 50% enrolment milestone has been achieved
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Update on MBC trial design following successful FDA meeting
- Commercial Scale in Manufacturing of Efti Achieved
- GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist
- Immutep enters 2nd collaboration with Pfizer and Merck KGaA
- Immutep receives A$1 million R&D Tax Incentive
Later from Immutep
- Enrolment Target Reached for INSIGHT-003 Trial in NSCLC
- Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
- Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
- Positive Final Data in 2nd Line Metastatic NSCLC Patients
- Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep